# Alzheimer's and Dementia Care: Stakeholders

## Who Is Affected

### Primary Stakeholders

| Group | Impact | Size |
|-------|--------|------|
| **People with dementia** | Cognitive decline, loss of independence, dignity | 6.7 million |
| **Family caregivers** | Time, health, financial burden | 11 million |
| **Spouses of those with dementia** | Intensive daily care, relationship changes | 2+ million |
| **Adult children caregivers** | Sandwich generation pressures | 5+ million |
| **Persons with early-onset** | Working age, young families affected | 200,000 |
| **Future persons with dementia** | Will need care system that works | Millions more |

### Demographics of Persons with Dementia

| Characteristic | Percentage |
|----------------|------------|
| Women | 66% |
| Age 85+ | 40% |
| White | 70% |
| Black | 14% |
| Hispanic | 10% |
| Living at home | 70% |
| Living alone | 25% |
| On Medicaid | 40% |

### Secondary Stakeholders

| Group | Connection | Interest |
|-------|------------|----------|
| **Healthcare providers** | Diagnosis, treatment, care | Training, reimbursement |
| **Nursing homes/memory care** | Institutional care delivery | Census, quality requirements |
| **Home care agencies** | Community-based care | Workforce, rates |
| **Medicare/Medicaid** | Financing care | Costs, quality |
| **Pharmaceutical industry** | Treatment development | Drug approval, pricing |
| **Employers** | Employees as caregivers | Productivity, retention |
| **Researchers** | Finding treatments, cure | Funding, participants |

## Who Has Power

### Federal Decision Makers

| Actor | Role | Power |
|-------|------|-------|
| **NIH/NIA** | Research funding and direction | Sets research priorities |
| **CMS Administrator** | Medicare/Medicaid coverage | Coverage decisions |
| **FDA** | Drug approval | Treatment access |
| **HHS Secretary** | National plan implementation | Policy priorities |
| **Congressional appropriators** | Research and program funding | Budget authority |
| **Senate HELP Committee** | Healthcare legislation | Authorization power |

### State Decision Makers

| Actor | Role | Power |
|-------|------|-------|
| **Governors** | State dementia plans | Program priorities |
| **State Medicaid directors** | HCBS waivers, rates | Service access |
| **State health officers** | BOLD Act implementation | Public health approach |
| **State units on aging** | AAA coordination | Local services |
| **Licensing boards** | Training requirements | Workforce standards |

### Industry Power

| Actor | Power Source | Influence |
|-------|--------------|-----------|
| **Alzheimer's Association** | 38 million+ advocates | Major lobbying force |
| **Pharmaceutical companies** | Drug development, pricing | Research direction |
| **Nursing home industry (AHCA)** | 14,000 facilities | Regulatory influence |
| **Memory care developers** | Growing sector | Market shaping |
| **Insurance industry** | Coverage decisions | Access to care |

### Research Community

| Actor | Role | Influence |
|-------|------|-----------|
| **NIH Alzheimer's Centers** | 30 research centers | Research direction |
| **Academic investigators** | Basic and clinical research | Scientific paradigms |
| **Biotech companies** | Novel drug development | Innovation pipeline |
| **Clinical trial networks** | Treatment testing | Drug development |

## Stakeholder Interests Matrix

### Position on Key Reforms

| Stakeholder | Research Funding | Care Coordination | Caregiver Support | LTC Coverage |
|-------------|------------------|-------------------|-------------------|--------------|
| Persons with dementia | Support | Strong support | Support | Strong support |
| Family caregivers | Support | Strong support | Strong support | Strong support |
| Alzheimer's Association | Strong support | Strong support | Strong support | Support |
| Pharma industry | Strong support | Neutral | Neutral | Neutral |
| Nursing home industry | Neutral | Conditional | Neutral | Support |
| Medicare | Conditional | Support | Conditional | Oppose (cost) |
| States | Support | Conditional | Conditional | Conditional |
| Researchers | Strong support | Neutral | Neutral | Neutral |

### Detailed Interests

#### Persons with Dementia

| Interest | Priority |
|----------|----------|
| Treatments that work | Critical |
| Dignity and autonomy | Critical |
| Remain at home | High |
| Quality care | Critical |
| Caregiver support | High |
| Advance planning respect | High |

#### Family Caregivers

| Interest | Priority |
|----------|----------|
| Respite care | Critical |
| Training and information | High |
| Financial assistance | High |
| Workplace flexibility | High |
| Care coordination | Critical |
| Emotional support | High |

#### Healthcare Providers

| Interest | Priority |
|----------|----------|
| Adequate reimbursement | Critical |
| Training resources | High |
| Reduced liability | High |
| Time for evaluation | High |
| Care coordination tools | Medium |
| Evidence-based guidelines | High |

#### Pharmaceutical Industry

| Interest | Priority |
|----------|----------|
| FDA approval pathway | Critical |
| Medicare coverage | Critical |
| Patent protection | High |
| Research funding | High |
| Pricing flexibility | Critical |
| Trial recruitment | High |

#### Research Community

| Interest | Priority |
|----------|----------|
| NIH funding | Critical |
| Participant recruitment | Critical |
| Diverse approaches | High |
| Academic freedom | High |
| Career pathways | Medium |
| Publication | High |

## Power Mapping

### Influence vs. Stakes Matrix

```text
                    HIGH STAKES
                        │
         Caregivers ▲   │    ▲  Persons with dementia
                        │
                        │
    Nursing    ●        │        ●  Alz Association
    home industry       │
                        │
LOW ────────────────────┼───────────────────── HIGH
INFLUENCE               │                   INFLUENCE
                        │
    General    ○        │        ◆  Pharma
    public              │           industry
                        │
         States    ◇    │    ◇  Research
                        │        community
                        │
                    LOW STAKES
```

### Coalition Dynamics

| Coalition | Members | Shared Interest |
|-----------|---------|-----------------|
| **Research advocacy** | Alz Association, researchers, some pharma | More funding |
| **Care quality** | Caregivers, consumer advocates, some providers | Better support services |
| **Industry alliance** | Pharma, device makers, providers | Coverage, payment |
| **Cost containment** | CMS, some states, fiscal hawks | Efficiency |
| **Caregiver support** | AARP, family groups, employers | Workplace/support policies |

## Generational Stakes

### Current Persons with Dementia (Silent/Boomers)

| Stake | Concern |
|-------|---------|
| Treatment access | New drugs available but expensive |
| Care quality | Will system meet their needs? |
| Financial security | Will savings last? |
| Dignity | Will they be respected? |
| Family burden | Worry about caregiver impact |

### Family Caregivers (Gen X, Millennials)

| Stake | Concern |
|-------|---------|
| Sandwich generation | Parents and children |
| Career impact | Can they keep working? |
| Own retirement | Depleted by parent care |
| Own dementia risk | Will they get disease? |
| System change | Will it be better for them? |

### Future Generations (Gen Z and beyond)

| Stake | Concern |
|-------|---------|
| Research success | Will there be a cure? |
| Prevention | Risk reduction options |
| System sustainability | Can society afford care? |
| Workforce | Who will provide care? |
| Innovation | New care models, technology |

## Geographic Stakeholders

### Rural Communities

| Stake | Challenge |
|-------|-----------|
| Specialist access | No neurologists nearby |
| Memory care | May not exist in region |
| Caregiver isolation | Fewer support resources |
| Transportation | Critical barrier |
| Telehealth | Connectivity issues |

### Urban Communities

| Stake | Challenge |
|-------|-----------|
| Cost of care | Higher in urban areas |
| Navigation | Complex, fragmented system |
| Diversity | Cultural competence needs |
| Housing | Integration with care |
| Workforce | Competition for workers |

### State Variation

| State Type | Stakes |
|------------|--------|
| High prevalence (FL, AZ) | Capacity challenges |
| Low Medicaid (TX, FL) | Access issues |
| HCBS leaders (OR, WA) | Maintaining gains |
| Rural states (WY, MT) | Geographic access |
| High cost (CA, NY) | Affordability |

## Stakeholder Engagement

### Who Has Been at the Table

| Forum | Typical Participants | Missing |
|-------|---------------------|---------|
| NIH advisory councils | Researchers, advocates | Families, persons with dementia |
| CMS coverage decisions | Industry, large advocates | Direct caregivers |
| State Medicaid planning | Providers, advocates | Diverse communities |
| FDA advisory committees | Scientists, patient advocates | Caregivers |

### Emerging Voices

| Group | Growing Influence |
|-------|-------------------|
| **Persons with dementia** | Speaking for selves |
| **Dementia advocates** | Social media activism |
| **Diverse communities** | Equity focus |
| **Younger caregivers** | Working caregiver voice |
| **Early-onset community** | Unique needs visibility |

### Underrepresented Stakeholders

| Group | Why Underrepresented |
|-------|---------------------|
| Black and Hispanic families | Historical exclusion, mistrust |
| Low-income caregivers | No time for advocacy |
| Rural residents | Geographic isolation |
| Persons with advanced dementia | Cannot self-advocate |
| Direct care workers | Not at policy tables |

## Stakeholder Mobilization Capacity

| Group | Resources | Organization | Track Record |
|-------|-----------|--------------|--------------|
| Alzheimer's Association | High | Strong | Major victories (NAPA, funding) |
| Family caregivers (AARP) | High | Strong | Mixed success |
| Persons with dementia | Low | Growing | Emerging voice |
| Research community | Medium | Moderate | Funding wins |
| Pharma industry | Very high | Strong | Drug approvals |
| Nursing home industry | High | Strong | Regulatory influence |

---

## Document Navigation

- Previous: [Root Causes](04-root-causes.md)
- Next: [Opposition](06-opposition.md)
